Each year, through the Linked Clinical Trials (LCT) initiative, drugs are selected by the Linked Clinical Trials committee, based on drug safety; the drug’s ability to pass the blood-brain barrier; mode of action relevant to putative disease mechanisms in Parkinson’s (PD); ability to measure the drug’s effectiveness; and whether there has been demonstrated success in several preclinical Parkinson’s models (Brundin et al 2013). 

At our annual LCT meeting in September 2017, the committee prioritised more compounds to be brought forward for further investigation: Twenty-one different treatment options were discussed, each with the potential to change the underlying disease processes. Some of the drugs discussed had general or non-specific actions, others were targeted with defined ways of measuring engagement in the brain.

Dossiers of each drug discussed were compiled by CPT’s director of research & development, Dr Richard Wyse. Included were three drugs where promising new findings have been published including UDCA, Alogliptin and Nortriptyline - trials of these prospective new Parkinson's treatments begin recruiting late 2018.

In the trial pipeline are: MSDC-0160, and NAC. 

Please help us drive forward our research to slow, stop, and reverse Parkinson's - donate today - thank you.